Overview
- Cofepris approved Qdenga’s sanitary registration on March 6, opening the door to commercialization in Mexico.
- Takeda has begun logistics for national availability, with initial access expected through private clinics and hospitals as public-program inclusion remains under review.
- Qdenga is a live-attenuated, two-dose vaccine reported to show 62% efficacy against infection and 83.6% efficacy against hospitalization.
- The TIDES phase‑3 study tracked more than 20,000 participants over seven years, supporting the vaccine’s safety profile and dosing schedule.
- Mexico has confirmed 896 dengue cases and no deaths through epidemiological week 7 of 2026, with most activity in Sonora, Sinaloa, Veracruz, Tabasco and Baja California Sur, following far higher totals in 2024.